Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
Drugs & Targets

FDA grants Orphan Drug Designation to iadademstat in SCLC

June 10, 2022
Vol.48 No.23
Drugs & Targets

FDA campaign aims to prevent e-cigarette use among AI/AN youth

June 10, 2022
Vol.48 No.23
In Brief

Reena Philip named associate director of biomarkers and precision oncology at OCE

June 03, 2022
Vol.48 No.22
Drugs & Targets

FDA approves two Opdivo-based regimens in unresectable advanced or metastatic ESCC

June 03, 2022
Vol.48 No.22
Drugs & Targets

FDA approves Kymriah in relapsed or refractory follicular lymphoma

June 03, 2022
Vol.48 No.22
Drugs & Targets

FDA grants priority review to Omblastys in pediatric CNS/leptomeningeal metastasis from neuroblastoma

June 03, 2022
Vol.48 No.22
Drugs & Targets

FDA grants Fast Track designation to PDS0101 + Keytruda in recurrent or metastatic HPV16-positive HNC

June 03, 2022
Vol.48 No.22
House Republicans seek information on “me-too” drugs developed in China
Capitol Hill

House Republicans seek information on “me-too” drugs developed in China

May 27, 2022
Vol.48 No.21
By Alice Tracey
Drugs & Targets

FDA grants marketing authorization to Parsortix System for liquid biopsy in MBC

May 27, 2022
Vol.48 No.21
Drugs & Targets

FDA approves Tibsovo + Vidaza in IDH1-mutant newly diagnosed AML

May 27, 2022
Vol.48 No.21

Posts navigation

Previous1…515253…58Next

Trending Stories

  • Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel
  • FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
    “Patients are owed another review.”
  • Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC
  • CDC’s recommendation to delay infant hepatitis B shot is likely to raise infections, JAMA studies show
  • CBER Director Vinay Prasad dared to “say no to drugs”
  • J. Craig Venter’s work was foundational to cancer advancement of the past 25 years

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2026 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account